Elitsur Y, Lichtman S N, Neace C, Dosescu J, Moshier J A
Department of Pediatrics, Marshall University School of Medicine, Huntington, WV 25701-0195, USA.
Immunopharmacology. 1998 Jan;38(3):279-85. doi: 10.1016/s0162-3109(97)00090-8.
Budesonide, a beta-adreno-receptor agonist, is comparable to corticosteroid in the treatment of patients with inflammatory bowel disease with the advantage of minimal side effect. Although the immunomodulatory effects of budesonide on the circulatory and respiratory mucosal immune system have been reported, its effect on the human gut immune system has not been published. In this study, the effect of budesonide on the human gut immune system was compared to methyl-prednisolone. The cellular immune function was measured in-vitro by DNA synthesis, ornithine decarboxylase (ODC) activity and TNFalpha secretion. We found that both drugs have a comparable inhibitory effect on DNA synthesis, ODC activity and suppression of TNFalpha secretion. Exogenous addition of IL-2, did not restore the antiproliferative effect of both drugs. We conclude that budesonide has a comparative suppressive effect to methyl-prednisolone on the gut immune system which is not related to IL-2 secretion. The antiproliferative response may explain the therapeutic effect of budesonide on patients with inflammatory bowel disease.
布地奈德是一种β-肾上腺素能受体激动剂,在治疗炎症性肠病患者方面与皮质类固醇相当,且副作用极小。尽管已报道布地奈德对循环和呼吸道黏膜免疫系统具有免疫调节作用,但其对人体肠道免疫系统的影响尚未见报道。在本研究中,将布地奈德对人体肠道免疫系统的影响与甲泼尼龙进行了比较。通过DNA合成、鸟氨酸脱羧酶(ODC)活性和肿瘤坏死因子α(TNFα)分泌在体外测定细胞免疫功能。我们发现两种药物对DNA合成、ODC活性和TNFα分泌的抑制作用相当。外源性添加白细胞介素-2(IL-2)并不能恢复两种药物的抗增殖作用。我们得出结论,布地奈德对肠道免疫系统的抑制作用与甲泼尼龙相当,且与IL-2分泌无关。抗增殖反应可能解释了布地奈德对炎症性肠病患者的治疗作用。